+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1207 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating a web-based decision support tool designed to help men make informed choices about vasectomy and other birth control options. The study aims to find out if using this tool improves mens knowledge about vasectomy and reduces conflict in their decision-making. The research focuses on men assigned male at birth who are considering vasectomy and wish to learn more about their options. Participants are randomly assigned to one of two groups. One group will use the web-based decision aid, while the other group will complete a survey without using the decision aid. The decision aid aims to provide evidence-based information to help participants align their choices with their values and reproductive goals. During the study, participants will complete surveys assessing their knowledge about vasectomy, their decision-making process, their interest in vasectomy, and experiences with healthcare navigation. Researchers will measure knowledge and decisional conflict related to contraceptive choices. The study is conducted over several months, with participation lasting up to 45 minutes per outcome measure.

Age: 21Years - 55YearsMALEPhase Not Applicable
2 locations
P

Actively Recruiting

Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.

Age: 18Years +All GendersPhase 3
126 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of two types of maxillary expanders used to widen the upper jaw in children aged 8 to 13 years with maxillary transverse deficiency. This trial compares a traditional expander made by hand in a laboratory to a newer expander designed on a computer and produced with 3D printing technology. The goal is to determine if the 3D-printed expander is as effective as the conventional one while potentially offering greater comfort to the patient. Participants will be randomly assigned to two groups one group receives the conventional laboratory-made Hyrax expander, and the other group receives the 3D-printed Hyrax expander. Both devices are used in the orthodontic clinic to treat upper jaw expansion. The treatment period includes follow-up visits over six months where dental photos, X-rays, and scans are taken to monitor progress. Patients and their parents or guardians will also complete online questionnaires about quality of life and pain experienced at various times during the study. During the study, participants will attend regular clinical visits for standard orthodontic follow-up, including photos, X-rays, and dental scans to assess the expanders effects. Researchers will measure changes in the midpalatal suture opening, interincisal diastema width, molar inclination, and maxillary arch widths after two weeks. Pain perception and oral health-related quality of life will also be evaluated using specific pain scales and questionnaires. This study lasts six months, with ongoing monitoring of treatment progress and patient comfort.

Age: 8Years - 13YearsAll GendersPhase Not Applicable
2 locations
P

Actively Recruiting

Researchers are evaluating a combination treatment involving 9-ING-41 elraglusib, retifanlimab, and modified FOLFIRINOX chemotherapy in patients with advanced pancreatic cancer who have not received prior systemic therapy for their advanced disease. This Phase 1b study aims to assess the safety, tolerability, and potential anti-tumor effects of this combination, based on the rationale that inhibiting GSK-3 along with PD-1 blockade may provide synergistic benefits. Retifanlimab, a PD-1 inhibitor, has shown tolerability in previous trials, and 9-ING-41 has demonstrated anti-cancer activity with an acceptable safety profile. Participants will receive chemotherapy consisting of oxaliplatin, leucovorin, irinotecan, and 5-FU every 14 days. Retifanlimab will be administered intravenously at 500 mg on day 1 of every other cycle, and 9-ING-41 will be given intravenously twice weekly for the first 4 cycles, then weekly thereafter. The study begins with a safety lead-in cohort of 6 patients, with possible dose adjustments based on safety, followed by an expansion cohort up to 12 patients total. During the study, participants will undergo various assessments including laboratory tests and imaging to monitor dose limiting toxicities up to 28 days after treatment starts. Researchers will also track disease control rates, response rates, survival times, and treatment-related adverse events for up to 42 months. Participants are required to comply with scheduled visits and procedures throughout the study duration, which runs until 2029.

Age: 18Years +All GendersPhase 1
1 location
P

Actively Recruiting

This research aims to study cocaine use disorder CUD, a chronic condition with frequent relapses and abstinence periods. Researchers are evaluating brain dopamine release triggered by amphetamine using special PET scans in people with CUD. The study also looks at brain receptor changes related to stress and relapse, focusing on nociceptin opioid peptide receptors NOP and their role in counteracting stress effects in the brain. Understanding these mechanisms may help develop medications to prevent relapse in CUD. Participants will undergo a baseline PET scan using the radiotracer C-11NPA, followed by an oral dose of d-amphetamine at 0.5 mgkg. After amphetamine administration, a second PET scan will measure dopamine release in the brains striatum region. This study builds on previous imaging of NOP receptors before and after a hydrocortisone challenge and will explore how dopamine release relates to NOP receptor expression. The trial uses a single group design without masking. During the study, participants will have PET scans before and 2.5 to 3 hours after amphetamine intake to measure changes in dopamine binding. Researchers will assess dopamine release as their main outcome, focusing on changes in binding potential in the brain. Participants must meet strict health and substance use criteria, and safety monitoring includes screening for medical conditions and medication use. The study duration extends until September 2028, with comprehensive evaluations to understand the brain chemistry behind addiction and relapse.

Age: 18Years - 55YearsAll GendersEarly Phase 1
1 location
T

Actively Recruiting

Researchers are evaluating the progress of chronic venous leg ulcers in adults using a non-bordered foam dressing. This prospective, open, multi-center, interventional study aims to track wound healing over a 6-week period or until the wound heals. The study focuses on venous leg ulcers that produce moderate to large amounts of fluid and includes 20 participants across centers in the US and Canada. All participants will use the ALLEVYN Non-Adhesive foam dressing as the primary absorbent dressing. This device combines a breathable top film, a highly absorbent foam core, and a non-adhesive wound contact layer designed for comfort and optimal moist wound healing. The dressing will be worn continuously and changed every week during the treatment period. Participants will attend seven visits a baseline visit followed by weekly visits up to six weeks. At each visit, wound progress will be assessed by measuring wound size and evaluating wound condition. Researchers will also monitor pain, comfort, quality of life, dressing performance, and safety throughout the study. The main outcome measured is wound progress from baseline to last follow-up, with additional assessments including wound area reduction, tissue changes, exudate characteristics, skin condition, and adverse events.

Age: 18Years +All GendersPhase Not Applicable
3 locations
T

Actively Recruiting

Researchers are evaluating the progress of chronic wounds, specifically venous leg ulcers VLU and diabetic foot ulcers DFU, using an absorbent dressing called Mepilex Up. This study is a prospective, open, multi-center, interventional trial designed to observe wound healing over a period of up to six weeks. The goal is to track changes in wound area and condition while participants receive treatment according to local standards of care. Participants will use the Mepilex Up dressing, which is a soft, silicone-based absorbent foam dressing designed to manage wound exudate and protect the skin. The dressing will be applied as the primary dressing and changed weekly for up to six weeks or until the wound heals. The study includes seven visits a baseline visit followed by weekly visits to monitor wound healing and dressing performance. During each visit, researchers will assess wound progress through measurements and evaluations of wound area, volume, tissue quality, exudate, and skin condition. Participants will report on pain, comfort, and quality of life related to wound care. Safety will be monitored at all visits. The total treatment period is a maximum of 44 days or until healing occurs, with detailed tracking of dressing wear time, wound changes, and any adverse events.

Age: 18Years +All GendersPhase Not Applicable
4 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.

Age: 18Years +All GendersPhase 1Phase 2
82 locations
P

Actively Recruiting

Researchers are studying the safety and initial effects of T3011, given directly into tumors, alone and combined with the intravenous drug pembrolizumab. This Phase 12a open-label study focuses on adults with advanced or metastatic solid tumors, including melanoma, head and neck squamous cell carcinoma HNSCC, sarcoma, cutaneous squamous cell carcinoma cSCC, and non-small cell lung cancer NSCLC. The study aims to find safe dose levels and assess how well these treatments are tolerated and work in these cancer types. The study involves several groups Phase 1 tests increasing doses of T3011 alone to determine a recommended dose. Phase 2a Part 1 evaluates T3011 alone in participants with melanoma, HNSCC, sarcoma, and cSCC. Phase 2a Part 2 studies T3011 with pembrolizumab in NSCLC patients. A rollover arm allows participants whose cancer progresses on T3011 alone to receive the combination treatment. T3011 is given as an intratumoral injection every two weeks, and pembrolizumab is given intravenously every three weeks when combined. Participants will have tumor biopsies, imaging, and laboratory tests to monitor safety, drug levels, and cancer response. Researchers will track side effects and measure outcomes like tumor response and survival for up to two years after the first dose. Safety and tolerability are closely followed throughout, with additional monitoring for immune responses and drug presence in bodily fluids. Participants may be followed for up to one year after their last treatment dose to assess overall survival and long-term effects.

Age: 18Years +All GendersPhase 1Phase 2
9 locations

1-10 of 1,207

1